570 likes | 686 Views
Webinar: Managing Asthma in the Job Corps Student. John Kulig, MD, MPH Lead Medical Specialist September 7 th and 15 th , 2011. Overview.
E N D
Webinar:Managing Asthma in the Job Corps Student John Kulig, MD, MPH Lead Medical Specialist September 7th and 15th, 2011
Overview Summary: This webinar will review the comprehensive outpatient management of asthma with the goals of improving asthma control and enhancing employability. This course is offered at an intermediate level. It will consist of lecture, a pre-test, post-test and a question and answer period. No prerequisite knowledge is required for this course.
Learning Objectives After this presentation, participants will be able to: • Describe the current National Heart Lung and Blood Institute (NHLBI) Asthma Guidelines for classifying severity, control, and stepwise management of asthma. • Apply updated Job Corps Treatment Guidelines for management of students with asthma. • Implement case management for all Job Corps students with asthma.
Pre-Test 1. African American students have higher rates of asthma than their white peers. True or False? 2. Twice daily use of an albuterol inhaler prevents wheezing in most students with persistent asthma. True or False? 3. Inhaled corticosteroids are the preferred first choice for controller medications. True or False? 4. Efficacy of albuterol diminishes with long-term use. True or False?
Definition of Asthma • reversible obstructive airway disease • airway inflammation • increased airway responsiveness
Fast Facts • Every day in America: • 40,000 people miss school or work due to asthma • 30,000 people have an asthma attack • 5,000 people visit the emergency room due to asthma • 1,000 people are admitted to the hospital due to asthma • 11 people die from asthma http://www.aafa.org
Key Points • In 2009, the prevalence of asthma increased to 7.7% among adults, 9.6% among all children, and 17.0% among black, non-Hispanic children. • In 2008, approximately half of persons with asthma reported having had at least one asthma attack during the preceding 12 months. • Medical expenses associated with asthma amounted to $3,259 per person per year during 2002--2007. • Good control of asthma includes self-management training, appropriate use of inhaled corticosteroids to prevent symptoms and attacks, and avoidance of environmental allergens and irritants. However, only approximately one third of persons with asthma had been given an asthma action plan as recommended. Ref: MMWR May 6, 2011 / 60(17);547-552
Asthma Mortality • Each day 11 Americans die from asthma. There are more than 4,000 deaths due to asthma each year, many of which are avoidable with proper treatment and care. In addition, asthma is indicated as “contributing factor” for nearly 7,000 other deaths each year. • Since 1980, asthma death rates overall have increased more than 50% among all genders, age groups and ethnic groups. The death rate for children under 19 years old has increased by nearly 80% percent since 1980. • More females die of asthma than males, and women account for nearly 65% of asthma deaths overall. • African Americans are three times more likely to die from asthma. African American women have the highest asthma mortality rate of all groups, more than 2.5 times higher than Caucasian women. http://www.aafa.org
Gonzalez v. Hanford Elementary School District Jury Awards $9 million in Asthma Death at School “A California jury that unanimously awarded a mother $9 million in damages for the death of her 11 year-old son from an asthma attack at school found the school district guilty of negligence for failing to inform parents of an unwritten school policy that would have allowed the child to carry an inhaler.” May 2002
Current asthma prevalence among adults --- Behavioral Risk Factor Surveillance System, United States, 2009
Current asthma prevalence,* by age group,† sex, and race/ethnicity --- National Health Interview Survey, United States, 2001--2009
Current asthma prevalence,* by age group,† sex, and race/ethnicity --- National Health Interview Survey, United States, 2001--2009
Precipitants • allergens • respiratory irritants • respiratory infections • physical exertion • cold air • medications • food additives • emotional stress • gastroesophageal reflux
Clinical Assessment • classification of asthma severity • onset of wheezing/precipitant • current medication regimen adherence • office measurements of peak flow • past severity—ER, hospitalization, ICU • color, respiratory distress, vital signs • auscultation of lungs • objective measures: PEFR, pulse oximetry
Asthma Severity Intermittent • symptoms < 2 days a week • nighttime awakenings < 2 times a month • albuterol HFA use < 2 days a week • no interference with normal activity • normal FEV1 between exacerbations
Asthma Severity Mild persistent • symptoms > 2 days a week, but not daily • nighttime awakenings 3-4 times a month • albuterol HFA use > 2 days a week, but not daily, and not more than one time on any day • minor limitation of normal activity • FEV1 > 80% of predicted
Asthma Severity Moderate persistent • symptoms daily • nighttime awakenings > once a week, but not nightly • albuterol HFA use daily • some limitation of normal activity • FEV1 > 60% but < 80% of predicted
Asthma Severity Severe persistent • symptoms throughout the day • nighttime awakenings often 7 times a week • albuterol HFA use several times per day • extremely limited activity • FEV1 < 60% of predicted
Classification of Asthma Control Well controlled: • symptoms < 2 days per week • albuterol HFA use < 2 days per week Not well controlled: • symptoms > 2 days per week • albuterol HFA use > 2 days per week Very poorly controlled: • symptoms throughout the day • albuterol HFA use several times per day
Environmental Control Measures • eliminate indoor allergens • house dust • animal dander/saliva • mites • cockroaches • indoor molds • vacuum cleaners • humidifiers • avoid outdoor allergens • pollen • molds • avoid indoor irritants • tobacco smoke • wood smoke • strong odors/sprays • air pollutants
Immunotherapy for Asthma • controversial in asthma • effective in certain allergies • monthly injections of allergen required • 3 to 5 year course of treatment • risk of anaphylaxis
Asthma Medications • long term control medicationsto prevent symptoms, maintain normal activity levels, and prevent exacerbations • quick relief medicationsto treat symptoms and exacerbations • all patients with persistent asthmarequire both classes of medication
Asthma Medication: Patient Concerns • fear of addiction • belief that efficacy diminishes with long-term use • confusing corticosteroids with anabolic steroids • fear of side effects • confusing preventive therapy with acute treatment of symptoms
Quick Relief: Steps 1-6 • short-acting bronchodilator: inhaled b2 agonists as need for symptoms • intensity of treatment depends on severity of exacerbation – up to 3 treatments at 20 minute intervals • increasing use of short-acting inhaled b2 agonists indicates the need for initial or additional long-term control therapy
Step 1 • No daily medication needed • SABA (albuterol HFA) only as needed
Step 2 One daily medication: • inhaled corticosteroid - low dose (preferred) • inhaled cromolyn or nedocromil • oral leukotriene receptor antagonist • oral sustained-release theophylline
Step 3 Daily medication: • low dose inhaled corticosteroid plus long-acting inhaled b2 agonist (preferred) or • medium dose inhaled corticosteroid (preferred) • low dose inhaled corticosteroid plus oral leukotriene receptor antagonist, theophylline or zileuton
Step 4 Daily medication: • medium dose inhaled corticosteroid plus long-acting inhaled b2 agonist (preferred) • medium dose inhaled corticosteroid plus oral leukotriene receptor antagonist, theophylline or zileuton
Step 5 Daily medication: • high dose inhaled corticosteroid plus long-acting inhaled b2 agonist (preferred) and • consider omalizumab for patients who have allergies
Step 6 Daily medication: • high dose inhaled corticosteroid plus long-acting inhaled b2 agonist plus oral corticosteroid (preferred) and • consider omalizumab for patients who have allergies
Short-Acting Inhaled b2 Agonists (SABA) • albuterol HFA (Ventolin/Proventil/ProAir) 2 puffs qid max • terbutaline (Brethaire) 2 puffs qid max • pirbuterol (Maxair) 2 puffs qid max • levalbuterol (Xopenex) inhalation solution
Inhaled Anticholinergic Bronchodilators • ipratropium bromide (Atrovent) • 2 puffs qid • ipratropium/albuterol (Combivent) • 2 puffs qid • both primarily indicated in adult COPD, not in asthma
Inhaled Mast Cell Stabilizers • cromolyn sodium (Intal) • 2-4 puffs qid • nedocromil (Tilade) • 2-4 puffs bid after control established
Inhaled Corticosteroids • beclomethasone (Qvar) • budesonide (Pulmicort) - Respules/Turbuhaler • flunisolide (Aerobid/Aerobid-M) • fluticasone (Flovent 44/110/220) • mometasone (Asmanex Twisthaler) • triamcinolone (Azmacort)
Oral Corticosteroids • prednisone • prednisolone • methylprednisolone • dosage 40-60 mg per day in single or two divided doses for 3-10 days
Long-Acting Inhaled b2 Agonist (LABA) • salmeterol (Serevent) • MDI aerosol - 2 puffs bid • DPI Diskus - 1 inhalation bid • formoterol (Foradil) • DPI Aerolizer - 1 capsule bid • LABA for long-term control only • leave inhaler at home • not indicated for quick relief use • use LABA only in combination with inhaled corticosteroids
Combination Therapy • fluticasone/salmeterol (Advair Diskus) • 1 inhalation bid • low steroid dose: 100/50 mcg • medium steroid dose: 250/50 mcg • high steroid dose: 500/50 mcg • budesonide/formoterol (Symbicort) • 1 inhalation bid • low steroid dose: 80/4.5 mcg • high steroid dose: 160/4.5 mcg
Oral Leukotriene Modifiers • montelukast (Singulair) • 10 mg once qhs • zafirlukast (Accolate) • 20 mg bid • one hour ac or two hours pc • zileuton (Zyflo) • 600 mg qid • monitor liver enzymes
Oral Sustained-Release Theophylline • sustained release preparations (Theo-Dur/Uni-Dur/Uniphyl/Slo-Phyllin) • 10-15 mg/kg/day divided q 8, 12, or 24 hr • monitor steady state theophylline levels • therapeutic peak blood level 5-15 mcg/mL